These results are similar to outcomes observed in the ASPIRE In-Home study, which was published in The New England Journal of Medicine in July of 2013. In both datasets, there were significantly fewer sensor glucose values in the hypoglycemic range in subjects using the Threshold Suspend feature compared to those in the control group using sensor-augmented pump therapy.
About the Retrospective Study
The effectiveness of the Threshold Suspend feature in the real-world setting was conducted by retrospectively analyzing anonymized, aggregated data from more than 20,000 users of the MiniMed 530G system who uploaded to the CareLink® Personal Therapy Management Software for Diabetes. MiniMed 530G users have discretion to turn Threshold Suspend on and off. The study design calculated the amount of time that users spent with Threshold Suspend turned on (82%) and compared performance data from that segment against user time spent with the feature turned off. Study endpoints were to evaluate Threshold Suspend impact on overall hypoglycemia and impact on night-time hypoglycemia.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
CareLink allows both patients and their healthcare providers to view critical information from the patient's insulin pump, CGM and blood glucose meter in order to optimize their diabetes management. The online software displays the information in charts, graphs and tables, making it easy to discover glucose patterns and trends and make therapy adjustments, as needed.
About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts:
Amanda Sheldon
Public Relations
+1-818-576-4826
Jeff Warren
Investor Relations
+1-763-505-2696
Back to HCB News
